 If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia B LEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 GLOBE NEWSWIRE uniQure N.V. NASDAQ: QURE, a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL ... The post uniQure announces positive CHMP opinion for etranacogene dezaparvovec gene therapy for adults with... 